華廈眼科(301267.SZ):目標是未來五年華廈管理的眼科醫院數量超過200家,連鎖視光中心數量達到200家
格隆匯4月27日丨華廈眼科(301267.SZ)於2023年4月24日16:00-17:00接受機構調研,董事長在致辭中表示,2023年以來,除1月份外,2月份起公司各項經營指標均已恢復至快車道,管理層對公司未來增長充滿信心。未來5年,我們將堅持“內生增長+外延併購”發展戰略,全面推進全國眼科醫療網絡佈局和眼科服務升級,計劃在國內24個省(直轄市)新建或併購眼科醫院和視光中心,目標是未來五年華廈管理的眼科醫院數量超過200家,連鎖視光中心數量達到200家,重點佈局人口較多、經濟較發達、消費能力較強的城市,當然同時也會考慮華廈眼科在當地是否具備突出競爭力。
未來5年,華廈眼科將錨定每年30%以上的業績增長目標不動搖,力爭用優異的業績回報股東、回饋社會。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.